Vice President and Region Head
Regional Sales Manager, Sales and Marketing
Region Head - Japan, Sales and Marketing
Customer Service Manager, API Marketing & Sales - North Asia
Executive Vice President – API R&D
CPHI Japan 2024 is a leading annual trade event focusing on the pharmaceutical industry in Japan. Held at the Tokyo Big Sight (East Halls 4, 5 & 6) from April 17th to 19th, 2024, the event brings together a comprehensive range of exhibitors and attendees from across the pharmaceutical supply chain.
CPHI Japan 2024 serves as a platform for industry stakeholders to connect, exchange information, and explore business opportunities within the Japanese pharmaceutical landscape.
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 180+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
2022
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
2020
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。
製品またはサービスへの参照を含むこのカタログの情報は、販売の申し出を構成するものではなく、販売の申し出を表すものとして解釈されるものではありません。有効な特許で保護された製品は、商用目的で提供または提供されません。ただし、そのような規制上の免除が存在する場合は、規制当局への提出を目的として、そのような製品の調査数量が提供される場合があります。購入者は、それぞれの市場の特許シナリオを独自に評価する必要があり、すべての特許関連の責任を負うものとします。インドで有効な特許に基づいて保護されている製品は、商用利用はできませんが、セクション 107A の目的には利用できます。